The nutrition industry has a role to play in shaping people's relationship with diet and exercise. This issue dives into the market factors, recent legislation, and consumer trends that present opportunities for supplement brands and their ingredient suppliers.

Much of the talk around weight management this year is going to get caught up in the buzz about GLP-1 drugs that we cover in this issue (see “Ozempic update,” page 5), but solutions matched to these new patterns of eating and working can’t start and end with pharmaceuticals

AI coupled with wearables, like the increasingly common continuous glucose monitors, may be the right accountability for some, but it’s not exactly clear how that moves past the early adopters (see “Tech comes to training,” page 20).

The story of “stop-blaming-it-on-COVID 10” may be more about weight management than sports nutrition, but we’ve known for decades that the two are impossible to pull apart in American culture. We know that countless brands straddle both markets, often with the same products, but we don’t know how they adapt to a post-COVID relationship to diet and exercise.